Top

Reactions Weekly

Published in:

01-11-2023 | Ceftazidime | Case report

Amikacin/ceftazidime/colistin

Lack of efficacy, neurological impairment in the form of somnolence and off-label use: 2 case reports

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Zavrelova A, et al. Superiority of ceftazidime off-label high-dose regimen in PK/PD target attainment during treatment of extensively drug-resistant Pseudomonas aeruginosa infections in cancer patients. British Journal of Clinical Pharmacology 89 : 1452-1461, No. 4, Jan 2023. Available from: URL: http://doi.org/10.1111/bcp.15612

Title: Amikacin/ceftazidime/colistin
Lack of efficacy, neurological impairment in the form of somnolence and off-label use: 2 case reports
Publication date: 01-11-2023
Publisher: Springer International Publishing
Keywords: Ceftazidime
Pseudomonas Aeruginosa
Amikacin
Somnolence
Pneumonia
Septic Shock
Leukemia
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-48963-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Amikacin/ceftazidime/colistin

Lack of efficacy, neurological impairment in the form of somnolence and off-label use: 2 case reports

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Multiple drugs

Mycophenolate-mofetil/prednisone/tacrolimus

Bupivacaine

Lithium/sertraline

Carbamazepine/sodium-valproate

Enbucrilate